Regeneron Pharmaceuticals, Inc. (REGN) is listed on NASDAQ and operates in the Biotechnology industry (Healthcare sector).
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi;...
| Rating | Analysts |
|---|---|
| Strong Buy | 0 |
| Buy | 32 |
| Hold | 16 |
| Sell | 0 |
| Strong Sell | 0 |
Regeneron Pharmaceuticals, Inc., founded in 1988 and headquartered in Tarrytown, New York, operates in the biotechnology industry within the healthcare sector. The company is engaged in the discovery, development, manufacturing, and commercialization of medicines for various diseases globally. Key products include EYLEA for eye conditions such as wet age-related macular degeneration and diabetic macular edema, and Dupixent for atopic dermatitis and asthma. Regeneron also offers Libtayo for cutaneous squamous cell carcinoma, Praluent for cardiovascular conditions, REGEN-COV for COVID-19, and Kevzara for rheumatoid arthritis. Additional products include Inmazeb for Zaire ebolavirus infection, ARCALYST for cryopyrin-associated periodic syndromes, and ZALTRAP for metastatic colorectal cancer. The company is also developing treatments for eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases, as well as cancer, pain, and hematologic conditions. Regeneron collaborates with several organizations, including Sanofi, Bayer, and Roche Pharmaceuticals, and has agreements with entities such as the U.S. Department of Health and Human Services and AstraZeneca PLC.
Over the past three fiscal years, the company has demonstrated a consistent growth trajectory, with revenue increasing at a 4.6% CAGR from $13.1 billion in 2023 to $14.3 billion in 2025. This growth has been accompanied by a robust increase in earnings per share, which rose at a 9.2% CAGR, reaching $41.48 by 2025. Despite the revenue growth, the operating margin experienced a consistent decrease, contracting by 8.2pp from 33.2% to 24.9%, which suggests rising operational costs or investments that have yet to translate into proportional revenue gains. However, the net margin improved by 1.3pp to 31.4%, indicating effective cost management or other efficiencies at the net income level. Cash generation remained strong, with free cash flow growing at a 5.5% CAGR to $4.1 billion, and the company maintained a net cash position, improving from -$27.1 million to -$412.2 million, highlighting a strengthened balance sheet. The company's cash conversion ratio of 1.11 suggests that earnings are well-supported by cash flows. Additionally, the interest coverage ratio improved significantly, reaching 120.4x, reflecting a strong ability to meet interest obligations. Despite the decrease in operating margin, the overall financial health appears robust, supported by strong liquidity ratios and a consistent increase in revenue per share, which underscores the company's ability to generate shareholder value.
Regeneron Pharmaceuticals recently reported its Q1 2026 earnings, revealing a strong financial performance with quarterly sales of $3.605 billion, surpassing the analyst consensus estimate. Earnings per share were reported at $9, exceeding expectations of $8. Despite these positive results, analysts have adjusted their forecasts downward, reflecting potential concerns about future performance. The company's revenue was bolstered by robust sales of Dupixent and Eylea HD, although total Eylea sales saw a decline of 10% to $941 million. In contrast, Eylea HD sales increased by 52% to $468 million, and Libtayo's sales surged by 54% year-over-year to $438 million. On the regulatory front, Regeneron received FDA approval for its gene therapy aimed at restoring hearing, which has prompted discussions about the stock's potential as a buy. Additionally, Regeneron has been recognized for its corporate sustainability, being named to the Dow Jones Best-in-Class World Index for the seventh consecutive year. The company also introduced new 2030 science-led responsibility goals, underscoring its commitment to responsible innovation. These developments highlight Regeneron's strategic focus on expanding its product portfolio and maintaining its leadership in corporate responsibility.
Regeneron Pharmaceuticals operates in the biotechnology and pharmaceutical industry, which is currently experiencing significant growth driven by advancements in immunotherapy, gene therapy, and personalized medicine. Key macro trends include increasing demand for innovative treatments, regulatory shifts towards faster drug approvals, and heightened competition from biosimilars and novel therapeutics. Management identifies strong demand for their flagship products, such as DUPIXENT and EYLEA HD, as key tailwinds. However, they also acknowledge potential headwinds from regulatory scrutiny on drug pricing and the impending introduction of biosimilars. Over the calls, the consistent focus has been on leveraging their robust R&D pipeline to maintain a competitive edge, while recent developments highlight their strategic collaborations and regulatory engagements to navigate these industry dynamics.
Regeneron reported strong performance in Q1 2026, with total revenues increasing by 19% year-over-year, driven by significant growth in key products like DUPIXENT and EYLEA HD. The success of DUPIXENT, which saw a 31% increase in net sales, is attributed to its broad application across multiple indications and geographies. EYLEA HD also showed impressive growth, with a 52% increase in sales, reflecting successful physician adoption and confidence in its clinical profile. Management expressed satisfaction with the commercial execution and the progress in their pipeline, including the FDA approval of Otarmeni for genetic hearing loss. Concerns were noted regarding the pending FDA decision on the EYLEA HD prefilled syringe, which could impact future sales. The narrative between the calls remained consistent, emphasizing the strength of their product portfolio and pipeline advancements, while also addressing regulatory and competitive challenges.
Regeneron's growth strategy focuses on expanding their product portfolio through R&D investments, strategic collaborations, and potential M&A activities. They are heavily investing in their pipeline, particularly in areas like immunology, oncology, and rare diseases, to sustain long-term growth. Management claims competitive advantages in their innovative R&D capabilities and established market presence with products like DUPIXENT. However, they acknowledge risks such as regulatory hurdles, competition from biosimilars, and execution challenges in expanding their manufacturing capabilities. Analysts questioned the potential impact of biosimilars on EYLEA sales and the strategic direction for DUPIXENT's lifecycle management. The tension in the thesis lies in balancing the need for innovation with regulatory compliance and competitive pressures. While the strategy is promising, the execution risks and regulatory uncertainties present significant challenges that investors should monitor closely.
Between the Q4 2025 and Q1 2026 calls, Regeneron demonstrated progress on several fronts. They delivered on their commitment to strong revenue growth, with DUPIXENT and EYLEA HD exceeding expectations. The anticipated FDA approval for Otarmeni was achieved, marking a milestone in their rare disease portfolio. However, the FDA decision on the EYLEA HD prefilled syringe was delayed, which management had expected by April 2026. This delay highlights a gap in execution, as regulatory approvals are critical for maintaining product momentum. Management's silence on certain pipeline developments, such as the progress of specific late-stage trials, suggests potential delays or strategic shifts. Overall, while Regeneron is delivering on many of its promises, the execution of regulatory and pipeline milestones remains an area to watch.
- Monitor the FDA's decision on the EYLEA HD prefilled syringe, expected in Q2 2026, as it is crucial for sustaining sales momentum.
- Track DUPIXENT's sales growth and market penetration across its multiple indications, particularly in new markets and age groups.
- Watch for updates on the regulatory approval of cemdisiran for generalized myasthenia gravis, anticipated in Q4 2026.
- Observe the progress of strategic collaborations, such as those with Telix and TriNetX, which could impact future pipeline developments.
- Keep an eye on the competitive landscape for biosimilars, especially concerning EYLEA, as new entrants could affect market share.